https://www.selleckchem.com/pr....oducts/lenalidomide-
5 vs. 0.7 kg/y, P .0001). Patients with DMD had a transient loss of ALM around age 12 y, an increase at age 14 y, then a further decline at age 16 y, remaining low thereafter. Males with DMD have progressive decline in lean mass with age and worsening functional mobility. DXA measurement of ALM may be useful for monitoring lean mass status in patients with DMD, providing valuable information for individual treatment plans and research endeavors. Males with DMD have progressive decline in lean mass with age and worsening
Like
Comment
Share
